Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Laurent Humeau Biography and Net Worth

Insider of Inovio Pharmaceuticals

As Chief Scientific Officer, Dr. Humeau works to ensure continuous and strategic growth of INOVIO’s pipeline by introducing a constant flow of innovative concepts and cycling them from early-stage discovery and development through clinical application and patient monitoring. He provides technical and strategic leadership across multiple teams that are essential to upstream and downstream verticals of clinical development.

Dr. Humeau leads with a collaborative spirit and deeply believes in the company’s core values. He is a valuable member of the leadership team who greatly contributes to INOVIO’s culture. Prior to INOVIO, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Dr. Humeau holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 University and a MS degree from Pierre & Marie Curie/Paris 6 University, Paris, France.

What is Laurent Humeau's net worth?: The estimated net worth of Laurent Humeau is at least $5,781.79 as of June 9th, 2021. Dr. Humeau owns 547 shares of Inovio Pharmaceuticals stock worth more than $5,782 as of April 27th. This net worth estimate does not reflect any other investments that Dr. Humeau may own. Additionally, Dr. Humeau receives an annual salary of $673,590.00 as Insider at Inovio Pharmaceuticals. Learn More about Laurent Humeau's net worth.
How old is Laurent Humeau?: Dr. Humeau is currently 57 years old. There are 3 older executives and no younger executives at Inovio Pharmaceuticals. The oldest executive at Inovio Pharmaceuticals is Mr. Peter D. Kies, Chief Financial Officer, who is 61 years old. Learn More on Laurent Humeau's age.
What is Laurent Humeau's salary?: As the Insider of Inovio Pharmaceuticals, Inc., Dr. Humeau earns $673,590.00 per year. There are 2 executives that earn more than Dr. Humeau. The highest earning executive at Inovio Pharmaceuticals is Dr. Jacqueline E. Shea Ph.D., CEO, President & Director, who commands a salary of $1,080,000.00 per year. Learn More on Laurent Humeau's salary.
How do I contact Laurent Humeau?: The corporate mailing address for Dr. Humeau and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Laurent Humeau's contact information.
Has Laurent Humeau been buying or selling shares of Inovio Pharmaceuticals?: Laurent Humeau has not been actively trading shares of Inovio Pharmaceuticals during the past quarter. Most recently, Laurent Humeau sold 71 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $1,306.08, for a transaction totalling $92,731.68. Following the completion of the sale, the insider now directly owns 547 shares of the company's stock, valued at $714,425.76. Learn More on Laurent Humeau's trading history.
Who are Inovio Pharmaceuticals' active insiders?: Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Laurent Humeau Insider Trading History at Inovio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	71	$1,306.08	$92,731.68	547
8/10/2020	Sell	135	$2,744.64	$370,526.40	305
6/22/2020	Sell	135	$2,116.80	$285,768.00	440
8/30/2019	Buy	31	$319.68	$9,910.08	349
6/5/2019	Buy	138	$360.00	$49,680.00	318

Laurent Humeau Buying and Selling Activity at Inovio Pharmaceuticals

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $10.57

$10.09

$10.70

50 Day Range

MA: $10.56

$7.66

$13.88

2 Week Range

Now: $10.57

$3.89

$14.75

Volume

193,321 shs

Average Volume

510,351 shs

Market Capitalization

$247.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Protect Yourself While There’s Still Time …

From Weiss Ratings | Ad